Efficacy and safety of filgotinib in patients with rheumatoid arthritis: week 156 interim results from a long-term extension study

Background Janus kinase inhibitors are an effective option for achieving sustained remission or low disease activity in patients with rheumatoid arthritis (RA) following inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs. Filgotinib is a Janus kinase 1–preferential...

Full description

Saved in:
Bibliographic Details
Main Authors: Hendrik Schulze-Koops, Tsutomu Takeuchi, Daniel Aletaha, Maya H Buch, Yoshiya Tanaka, Ricardo Blanco, Paul Emery, Jacques-Eric Gottenberg, Bernard G Combe, Roberto Caporali, Patrick Verschueren, Vijay Rajendran, Anna Zubrzycka-Sienkiewicz, Edmund V Ekoka Omoruyi, Francesco De Leonardis
Format: Article
Language:English
Published: BMJ Publishing Group 2024-10-01
Series:RMD Open
Online Access:https://rmdopen.bmj.com/content/10/4/e004476.full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832591174350667776
author Hendrik Schulze-Koops
Tsutomu Takeuchi
Daniel Aletaha
Maya H Buch
Yoshiya Tanaka
Ricardo Blanco
Paul Emery
Jacques-Eric Gottenberg
Bernard G Combe
Roberto Caporali
Patrick Verschueren
Vijay Rajendran
Anna Zubrzycka-Sienkiewicz
Edmund V Ekoka Omoruyi
Francesco De Leonardis
author_facet Hendrik Schulze-Koops
Tsutomu Takeuchi
Daniel Aletaha
Maya H Buch
Yoshiya Tanaka
Ricardo Blanco
Paul Emery
Jacques-Eric Gottenberg
Bernard G Combe
Roberto Caporali
Patrick Verschueren
Vijay Rajendran
Anna Zubrzycka-Sienkiewicz
Edmund V Ekoka Omoruyi
Francesco De Leonardis
author_sort Hendrik Schulze-Koops
collection DOAJ
description Background Janus kinase inhibitors are an effective option for achieving sustained remission or low disease activity in patients with rheumatoid arthritis (RA) following inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs. Filgotinib is a Janus kinase 1–preferential inhibitor available in two doses for moderate-to-severe RA. We report the long-term efficacy and safety of filgotinib.Methods In the ongoing long-term extension study FINCH 4 (NCT03025308), patients continue filgotinib 200 mg or 100 mg from FINCH 1, 2 or 3 or receive filgotinib 200 mg or 100 mg de novo. Efficacy assessments up to week 156 include American College of Rheumatology 20% response (ACR20), Disease Activity Score 28 using C-reactive protein of <2.6, Clinical Disease Activity Index of ≤2.8, Simplified Disease Activity Index of ≤3.3 and Boolean remission (1.0 and 2.0) with non-responder imputation.Results In patients with an inadequate response to methotrexate, 60.2% and 54.6% receiving de novo filgotinib 200 mg and 100 mg had an ACR20 at week 156, respectively, as did 67.3% and 59.5% of those who continued filgotinib 200 mg and 100 mg. At week 156, Boolean remission 1.0 was achieved by 18.8% and 15.4% of patients treated with de novo filgotinib 200 mg and 100 mg, respectively, and by 21.1% and 18.5% when Boolean 2.0 criteria were applied. Similar efficacy data were seen in patients from FINCH 2 and 3. Safety data were consistent with the known safety profile of filgotinib.Conclusion In FINCH 4, filgotinib 200 mg and 100 mg (continuous or de novo) demonstrated sustained efficacy up to week 156 in patients enrolled from FINCH 1, 2 or 3, with no unexpected safety results.
format Article
id doaj-art-876c49e5e08a4163a919ba3850e5bc79
institution Kabale University
issn 2056-5933
language English
publishDate 2024-10-01
publisher BMJ Publishing Group
record_format Article
series RMD Open
spelling doaj-art-876c49e5e08a4163a919ba3850e5bc792025-01-23T01:05:08ZengBMJ Publishing GroupRMD Open2056-59332024-10-0110410.1136/rmdopen-2024-004476Efficacy and safety of filgotinib in patients with rheumatoid arthritis: week 156 interim results from a long-term extension studyHendrik Schulze-Koops0Tsutomu Takeuchi1Daniel Aletaha2Maya H Buch3Yoshiya Tanaka4Ricardo Blanco5Paul Emery6Jacques-Eric Gottenberg7Bernard G Combe8Roberto Caporali9Patrick Verschueren10Vijay Rajendran11Anna Zubrzycka-Sienkiewicz12Edmund V Ekoka Omoruyi13Francesco De Leonardis14Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, Ludwig Maximilian University of Munich, Munich, GermanyKeio University, Tokyo, JapanDivision of Rheumatology, Medical University of Vienna, Vienna, AustriaCentre for Musculoskeletal Research, University of Manchester, Manchester, UK5 University of Occupational and Environmental Health, Kitakyushu, JapanImmunopathology group, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Cantabria, SpainNIHR Leeds Biomedical Research Centre, Leeds, UKRheumatology, Hopitaux universitaires de Strasbourg, Strasbourg, FranceRheumatology, Montpellier University, Montpellier, Occitanie, FranceUniversity of Milan, Milan, ItalyDepartment of Rheumatology, KU Leuven and University Hospital Leuven, Leuven, BelgiumGalapagos NV, Mechelen, BelgiumARS Rheumatica, Warsaw, PolandGalapagos NV, Mechelen, BelgiumGalapagos GmbH, Basel, SwitzerlandBackground Janus kinase inhibitors are an effective option for achieving sustained remission or low disease activity in patients with rheumatoid arthritis (RA) following inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs. Filgotinib is a Janus kinase 1–preferential inhibitor available in two doses for moderate-to-severe RA. We report the long-term efficacy and safety of filgotinib.Methods In the ongoing long-term extension study FINCH 4 (NCT03025308), patients continue filgotinib 200 mg or 100 mg from FINCH 1, 2 or 3 or receive filgotinib 200 mg or 100 mg de novo. Efficacy assessments up to week 156 include American College of Rheumatology 20% response (ACR20), Disease Activity Score 28 using C-reactive protein of <2.6, Clinical Disease Activity Index of ≤2.8, Simplified Disease Activity Index of ≤3.3 and Boolean remission (1.0 and 2.0) with non-responder imputation.Results In patients with an inadequate response to methotrexate, 60.2% and 54.6% receiving de novo filgotinib 200 mg and 100 mg had an ACR20 at week 156, respectively, as did 67.3% and 59.5% of those who continued filgotinib 200 mg and 100 mg. At week 156, Boolean remission 1.0 was achieved by 18.8% and 15.4% of patients treated with de novo filgotinib 200 mg and 100 mg, respectively, and by 21.1% and 18.5% when Boolean 2.0 criteria were applied. Similar efficacy data were seen in patients from FINCH 2 and 3. Safety data were consistent with the known safety profile of filgotinib.Conclusion In FINCH 4, filgotinib 200 mg and 100 mg (continuous or de novo) demonstrated sustained efficacy up to week 156 in patients enrolled from FINCH 1, 2 or 3, with no unexpected safety results.https://rmdopen.bmj.com/content/10/4/e004476.full
spellingShingle Hendrik Schulze-Koops
Tsutomu Takeuchi
Daniel Aletaha
Maya H Buch
Yoshiya Tanaka
Ricardo Blanco
Paul Emery
Jacques-Eric Gottenberg
Bernard G Combe
Roberto Caporali
Patrick Verschueren
Vijay Rajendran
Anna Zubrzycka-Sienkiewicz
Edmund V Ekoka Omoruyi
Francesco De Leonardis
Efficacy and safety of filgotinib in patients with rheumatoid arthritis: week 156 interim results from a long-term extension study
RMD Open
title Efficacy and safety of filgotinib in patients with rheumatoid arthritis: week 156 interim results from a long-term extension study
title_full Efficacy and safety of filgotinib in patients with rheumatoid arthritis: week 156 interim results from a long-term extension study
title_fullStr Efficacy and safety of filgotinib in patients with rheumatoid arthritis: week 156 interim results from a long-term extension study
title_full_unstemmed Efficacy and safety of filgotinib in patients with rheumatoid arthritis: week 156 interim results from a long-term extension study
title_short Efficacy and safety of filgotinib in patients with rheumatoid arthritis: week 156 interim results from a long-term extension study
title_sort efficacy and safety of filgotinib in patients with rheumatoid arthritis week 156 interim results from a long term extension study
url https://rmdopen.bmj.com/content/10/4/e004476.full
work_keys_str_mv AT hendrikschulzekoops efficacyandsafetyoffilgotinibinpatientswithrheumatoidarthritisweek156interimresultsfromalongtermextensionstudy
AT tsutomutakeuchi efficacyandsafetyoffilgotinibinpatientswithrheumatoidarthritisweek156interimresultsfromalongtermextensionstudy
AT danielaletaha efficacyandsafetyoffilgotinibinpatientswithrheumatoidarthritisweek156interimresultsfromalongtermextensionstudy
AT mayahbuch efficacyandsafetyoffilgotinibinpatientswithrheumatoidarthritisweek156interimresultsfromalongtermextensionstudy
AT yoshiyatanaka efficacyandsafetyoffilgotinibinpatientswithrheumatoidarthritisweek156interimresultsfromalongtermextensionstudy
AT ricardoblanco efficacyandsafetyoffilgotinibinpatientswithrheumatoidarthritisweek156interimresultsfromalongtermextensionstudy
AT paulemery efficacyandsafetyoffilgotinibinpatientswithrheumatoidarthritisweek156interimresultsfromalongtermextensionstudy
AT jacquesericgottenberg efficacyandsafetyoffilgotinibinpatientswithrheumatoidarthritisweek156interimresultsfromalongtermextensionstudy
AT bernardgcombe efficacyandsafetyoffilgotinibinpatientswithrheumatoidarthritisweek156interimresultsfromalongtermextensionstudy
AT robertocaporali efficacyandsafetyoffilgotinibinpatientswithrheumatoidarthritisweek156interimresultsfromalongtermextensionstudy
AT patrickverschueren efficacyandsafetyoffilgotinibinpatientswithrheumatoidarthritisweek156interimresultsfromalongtermextensionstudy
AT vijayrajendran efficacyandsafetyoffilgotinibinpatientswithrheumatoidarthritisweek156interimresultsfromalongtermextensionstudy
AT annazubrzyckasienkiewicz efficacyandsafetyoffilgotinibinpatientswithrheumatoidarthritisweek156interimresultsfromalongtermextensionstudy
AT edmundvekokaomoruyi efficacyandsafetyoffilgotinibinpatientswithrheumatoidarthritisweek156interimresultsfromalongtermextensionstudy
AT francescodeleonardis efficacyandsafetyoffilgotinibinpatientswithrheumatoidarthritisweek156interimresultsfromalongtermextensionstudy